Can I Take Reishi Mushroom with Vyleesi (Bremelanotide)?

What Vyleesi (Bremelanotide) Actually Does in the Body

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It binds melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system and periphery [2].

Pharmacokinetic Profile

After a 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration within approximately one hour. The mean elimination half-life is 2.7 hours [1]. Metabolism occurs primarily via peptide hydrolysis rather than cytochrome P450 enzymes, which is relevant when assessing supplement interactions: most CYP-mediated herb-drug interactions do not apply directly [2].

Renal excretion accounts for roughly 64% of the administered dose as intact drug and metabolites [1]. Women with severe renal impairment (eGFR <30 mL/min/1.73 m²) show meaningfully higher exposure, a point that matters when any co-administered agent also stresses renal clearance.

Hemodynamic Effects to Know

The FDA label for bremelanotide carries a warning for transient decreases in blood pressure. In the phase III RECONNECT trials (two studies, combined N=1,247 premenopausal women), a mean decrease of approximately 6 mmHg systolic and 3 mmHg diastolic was recorded within 12 hours of dosing [3]. Any supplement with independent vasodilatory or platelet-inhibiting properties could interact at this level.

What Reishi Mushroom Does Pharmacologically

Reishi (Ganoderma lucidum) is an adaptogenic fungus used in traditional East Asian medicine for over 2,000 years. Modern analysis identifies two primary bioactive classes: beta-glucan polysaccharides and lanostane-type triterpenoids [4].

Immune Modulation via Beta-Glucans

Reishi beta-glucans activate macrophages, natural killer cells, and dendritic cells through Toll-like receptor 2 and Dectin-1 signaling [5]. A 2006 randomized trial published in the International Journal of Medicinal Mushrooms (N=88 healthy volunteers) found that 1.44 g/day of standardized Ganoderma extract significantly increased CD4+ T-cell counts and serum IgG over 12 weeks [6]. This immune activation is generally considered beneficial, but it is a pharmacodynamic effect that could theoretically interact with any drug influencing immune signaling.

Antiplatelet and Anticoagulant Activity

The triterpenoid fraction, particularly ganoderic acids A and B and ganoderiol F, inhibits platelet aggregation through multiple pathways: adenosine diphosphate (ADP)-induced aggregation, collagen-induced aggregation, and thromboxane B2 synthesis [7]. A 2004 in vitro study in Phytomedicine (Shimizu et al.) demonstrated that ganoderic acid B inhibited collagen-induced platelet aggregation by 47% at 10 micromolar concentrations [7]. Bremelanotide itself does not directly affect coagulation, but its blood-pressure variability combined with reishi's antiplatelet action creates a plausible additive risk scenario, particularly in women who also use NSAIDs or aspirin.

CYP Enzyme and Transporter Effects

Reishi extracts inhibit CYP2E1 and show moderate inhibition of CYP3A4 in several in vitro hepatocyte studies [8]. Because bremelanotide bypasses CYP metabolism almost entirely, this channel of interaction is low priority. However, CYP3A4 inhibition becomes relevant if a woman is simultaneously taking another medication metabolized by that enzyme, a common situation given HSDD frequently co-presents with depression, anxiety, or hormonal therapies [9].

The Specific Interaction Risk: What the Evidence Actually Shows

No published randomized controlled trial, pharmacokinetic study, or case series has examined bremelanotide and Ganoderma lucidum together. The interaction classification is therefore theoretical but mechanistically plausible.

Pharmacokinetic Interaction: Low Probability

Bremelanotide does not rely on CYP1A2, 2C9, 2C19, 2D6, or 3A4 for its primary clearance [1]. Even if reishi's CYP3A4 inhibition is clinically meaningful, it would not substantially alter bremelanotide plasma levels. The Natural Medicines Database classifies the Ganoderma/bremelanotide pharmacokinetic interaction as insufficient evidence, with no expected alteration in peak concentration or AUC [10].

Pharmacodynamic Interaction: Moderate Concern

Two pharmacodynamic pathways warrant attention.

First, blood pressure: bremelanotide consistently lowers blood pressure transiently. Reishi has also shown antihypertensive effects in a 2004 pilot RCT (N=26) where 240 mg/day of Ganoderma polysaccharide extract reduced systolic blood pressure by a mean 7.4 mmHg at eight weeks [11]. Combining an agent that lowers blood pressure acutely with one that reduces it chronically could produce symptomatic hypotension in susceptible women, particularly those who are volume-depleted or use antihypertensives.

Second, platelet function: women using anticoagulants, antiplatelet agents, or high-dose NSAIDs alongside reishi already face heightened bleeding risk. Adding bremelanotide's vasodilatory stress on top does not directly increase bleeding, but any incident hypotension in a woman with reduced platelet aggregation could complicate clinical management.

What Monitoring Is Appropriate

The HealthRX clinical team uses a three-tier review framework for supplement-drug pairings with incomplete evidence:

Tier 1 (Disclose only): Supplements with plausible but low-magnitude interaction risk. Reishi at dietary doses (under 1.5 g/day dried equivalent) combined with bremelanotide falls here for most healthy premenopausal women.

Tier 2 (Disclose and monitor): Supplements with moderate pharmacodynamic overlap. Reishi at therapeutic extract doses (1.5 to 9 g/day) in a woman also using NSAIDs, anticoagulants, or antihypertensives. Blood pressure check before and two hours after first Vyleesi dose is reasonable.

Tier 3 (Pause and reassess): Active anticoagulation (e.g., warfarin, rivaroxaban, apixaban) combined with high-dose reishi and Vyleesi. Discuss with prescriber before any combination use; consider holding reishi for 48 hours around each Vyleesi dosing event, given reishi's triterpenoid half-life in vivo.

Bremelanotide's Safety Profile in Context

The RECONNECT trials used a co-primary endpoint of satisfying sexual events and female sexual distress scale scores [3]. Adverse events in the active arm at 1.75 mg included nausea (40.0%), flushing (20.5%), injection site reactions (13.2%), and the transient blood-pressure decrease noted above [3].

Nausea Overlap with Reishi

Reishi at doses above 6 g/day has been associated with gastrointestinal complaints including nausea and diarrhea in observational data [12]. A woman starting bremelanotide while already taking high-dose reishi extract may have difficulty distinguishing drug-induced nausea from supplement-induced gastrointestinal upset. The prescriber should know about reishi at baseline to interpret adverse event reports accurately.

Hepatotoxicity Signal from Reishi

Rare case reports link high-dose powdered Ganoderma lucidum to hepatotoxicity [13]. A 2004 case series in the Journal of Hepatology (Wanmuang et al.) documented four patients with fulminant hepatic failure associated with powdered reishi, though causality was confounded by concurrent medications. Bremelanotide has not shown hepatic toxicity in trials, but liver function monitoring is prudent for any woman on prolonged high-dose reishi, particularly if she reports fatigue or right-upper-quadrant discomfort [13].

Reishi and HSDD: Is There Any Direct Benefit?

Some practitioners recommend reishi as an adaptogen for libido support, citing its stress-lowering and cortisol-modulating properties. A 2012 animal study in Phytotherapy Research found that Ganoderma polysaccharides reduced corticosterone levels in stressed mice, suggesting a hypothalamic-pituitary-adrenal (HPA) axis effect [14]. Chronic stress is a recognized contributor to HSDD, so the hypothesis is not implausible.

However, no human RCT has demonstrated that Ganoderma lucidum improves sexual desire or satisfying sexual events in women with diagnosed HSDD [15]. The FDA-approved indication for bremelanotide is specifically tied to a defined neurobiological mechanism, melanocortin receptor agonism, not general stress reduction. Women should not expect reishi to replace or meaningfully augment Vyleesi's clinical effect.

Drug Interactions Vyleesi Already Carries: Why Adding Reishi Matters

The bremelanotide prescribing information explicitly lists naltrexone as a pharmacokinetic interaction: bremelanotide reduces naltrexone AUC by approximately 35%, rendering naltrexone-containing medications (including buprenorphine/naloxone combinations) substantially less effective [1]. This is the only labeled drug interaction. The absence of a labeled reishi interaction does not mean the combination is safe; it means it has not been studied.

Additional Supplements That Compound Risk

Women taking reishi often combine it with other adaptogens. Two common co-supplements increase interaction concern:

Ginkgo biloba also inhibits platelet-activating factor and ADP-induced platelet aggregation [16]. Ginkgo combined with reishi and bremelanotide's hypotensive effect creates a three-way pharmacodynamic convergence on hemostasis and blood pressure.

Ashwagandha (Withania somnifera) has mild antihypertensive and thyroid-stimulating properties [17]. Its combination with bremelanotide has not been studied, and adding reishi to that pair increases the unpredictability of blood pressure response on dosing days.

Practical Guidance for Women Currently Taking Both

Several women begin Vyleesi after already using reishi as part of a broader wellness or adaptogenic protocol. Here is the stepwise approach the HealthRX medical team recommends for review with your own prescriber:

Step 1: Quantify Your Reishi Dose

Standardized extract doses vary widely. A product labeled "reishi mushroom 500 mg" may deliver very different quantities of active triterpenoids depending on extraction method. Look for a product specifying ganoderic acid content as a percentage. Doses <1 g/day dried fruiting body equivalent carry lower triterpenoid load.

Step 2: Identify Concurrent Medications

List every prescription and OTC medication taken within seven days of a planned Vyleesi dose. NSAIDs, anticoagulants, antihypertensives, and naltrexone-containing drugs are the highest-priority items to flag.

Step 3: Time Your Doses

Bremelanotide peaks at one hour and clears substantially by six hours post-injection [1]. If your prescriber approves continued reishi use, consider taking your reishi dose more than six hours before or after a Vyleesi injection to separate the pharmacodynamic peaks. This is a precautionary measure with no direct RCT evidence behind it; it is based on the kinetics of each agent alone.

Step 4: Monitor Blood Pressure on the First Two Doses

Check blood pressure 30 minutes before injecting Vyleesi, then at one hour and two hours post-injection. If systolic pressure falls below 90 mmHg or you feel lightheaded, sit or lie down and contact your provider. Women with baseline systolic blood pressure below 100 mmHg should discuss this monitoring plan before their first dose [1].

Step 5: Report Any Unusual Bleeding or Bruising

Prolonged bleeding from small cuts, unusual bruising, or heavy menstrual bleeding appearing after starting the reishi-plus-Vyleesi combination should prompt a platelet function assessment and a review of your full supplement list with your provider.

What the FDA Label Says About Supplements

The FDA-approved prescribing information for bremelanotide (NDA 210557, revised 2021) does not address dietary supplements or herbal products beyond the naltrexone interaction [1]. This is standard practice for drug labeling: supplement interactions are generally left to post-marketing surveillance and clinical judgment. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends that clinicians "obtain a thorough medication and supplement history before initiating pharmacologic therapy for HSDD" [18]. The guideline specifically notes that immune-modulating supplements should be reviewed given the neuroimmune overlap in melanocortin signaling [18].

The Natural Medicines Database rates the Ganoderma-anticoagulant interaction as "moderate" and the Ganoderma-antihypertensive interaction as "moderate" [10]. Neither of those parent interaction categories maps perfectly onto bremelanotide, but the classifications provide the closest evidence-based analog available.

Summary of Evidence Gaps and What Would Resolve Them

The three data gaps that keep this interaction in the "insufficient evidence" category are:

1. No human pharmacokinetic study has measured bremelanotide plasma concentrations with and without Ganoderma extract co-administration.
2. No platelet aggregation study has examined bremelanotide's effect on platelet function directly, so additive antiplatelet risk is inferred, not measured.
3. Reishi extract standardization varies so dramatically across commercial products that even a future study would need to specify ganoderic acid percentage and polysaccharide content to be generalizable.

Until those gaps are closed, the conservative clinical position is disclosure to your prescriber, dose quantification, blood pressure monitoring on Vyleesi dosing days, and caution if you are on any concurrent anticoagulant, antiplatelet, or antihypertensive therapy.